Breast cancer screening tacked on more than $1 billion to Medicare costs, but its effect on Medicare patient outcomes remains unclear, according to a study published online Jan. 7 in JAMA Internal Medicine. The researchers suggested overdiagnosis in higher-cost regions, and also cautioned that the cost curve may grow steeper as Medicare covers newer screening modalities without proof of impact on outcomes.